Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016', provides an overview of the Hyundai Pharmaceutical Co Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Hyundai Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Hyundai Pharmaceutical Co Ltd
- The report provides overview of Hyundai Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Hyundai Pharmaceutical Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Hyundai Pharmaceutical Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Hyundai Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hyundai Pharmaceutical Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyundai Pharmaceutical Co Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyundai Pharmaceutical Co Ltd Snapshot 7
Hyundai Pharmaceutical Co Ltd Overview 7
Key Facts 7
Hyundai Pharmaceutical Co Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Hyundai Pharmaceutical Co Ltd - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Hyundai Pharmaceutical Co Ltd - Pipeline Products Glance 14
Hyundai Pharmaceutical Co Ltd - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Hyundai Pharmaceutical Co Ltd - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Hyundai Pharmaceutical Co Ltd - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Hyundai Pharmaceutical Co Ltd - Drug Profiles 19
BPS-015 SR - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
choline alfoscerate SR - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
HD-0471042 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
HD-0471953 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
HD-6277 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
HOB-046 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
HOB-047 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
HOB-051 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HOB-060 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
HOB-071 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
HOB-075 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
HTB-005 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HTB-006 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
levodropropizine CR - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
tranexamic acid - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
UHC-1 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Hyundai Pharmaceutical Co Ltd - Pipeline Analysis 35
Hyundai Pharmaceutical Co Ltd - Pipeline Products by Target 35
Hyundai Pharmaceutical Co Ltd - Pipeline Products by Route of Administration 36
Hyundai Pharmaceutical Co Ltd - Pipeline Products by Molecule Type 37
Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action 38
Hyundai Pharmaceutical Co Ltd - Dormant Projects 39
Hyundai Pharmaceutical Co Ltd - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Hyundai Pharmaceutical Co Ltd, Key Facts 7
Hyundai Pharmaceutical Co Ltd - Pipeline by Indication, 2016 9
Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016 10
Hyundai Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016 11
Hyundai Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016 12
Hyundai Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 13
Hyundai Pharmaceutical Co Ltd - Phase III, 2016 14
Hyundai Pharmaceutical Co Ltd - Phase II, 2016 15
Hyundai Pharmaceutical Co Ltd - Phase I, 2016 16
Hyundai Pharmaceutical Co Ltd - Preclinical, 2016 17
Hyundai Pharmaceutical Co Ltd - Discovery, 2016 18
Hyundai Pharmaceutical Co Ltd - Pipeline by Target, 2016 35
Hyundai Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016 36
Hyundai Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016 37
Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016 38
Hyundai Pharmaceutical Co Ltd - Dormant Developmental Projects,2016 39